The goal of this clinical trial is to find out whether a synbiotic formula (SGR11) can improve symptoms and health measures in people with inflammatory bowel disease (IBD). The main questions it aims to answer are:
* Does SGR11 lead to overall improvement in a participant's condition after 8 weeks, as measured by the Clinical Global Impression-Improvement Scale (CGI I)?
* Is SGR11 safe and well tolerated in people with IBD?
Participants will:
* Take the study synbiotic formula (SGR11) daily for 8 weeks
* Complete symptom and quality of life questionnaires
* Provide stool samples and, if applicable, blood samples to measure inflammation and gut microbiome changes
* Report any side effects that occur during the study